Icosavax Inc (NASDAQ:ICVX) – Equities research analysts at Jefferies Financial Group issued their FY2021 earnings per share estimates for shares of Icosavax in a research report issued to clients and investors on Wednesday, December 29th. Jefferies Financial Group analyst R. Song anticipates that the company will post earnings of ($2.97) per share for the year. Jefferies Financial Group has a “Buy” rating and a $50.00 price objective on the stock. Jefferies Financial Group also issued estimates for Icosavax’s Q4 2021 earnings at ($0.34) EPS, FY2022 earnings at ($1.15) EPS, FY2023 earnings at ($1.26) EPS, FY2024 earnings at ($0.73) EPS and FY2025 earnings at $0.46 EPS. Icosavax (NASDAQ:ICVX) last issued its quarterly earnings data on Monday, November 15th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.81). The business had revenue of $1.83 million for the quarter, compared to analysts’ expectations of $3.30 million.
Separately, Zacks Investment Research cut shares of Icosavax from a “hold” rating to a “sell” rating in a research note on Thursday, November 18th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $48.57.
Shares of NASDAQ:ICVX opened at $23.02 on Friday. The company has a 50 day moving average price of $25.17. Icosavax has a 1 year low of $19.14 and a 1 year high of $49.99.
A number of hedge funds have recently modified their holdings of ICVX. Royal Bank of Canada bought a new stake in Icosavax in the 3rd quarter worth about $44,000. Citigroup Inc. bought a new position in shares of Icosavax during the 3rd quarter valued at approximately $45,000. Metropolitan Life Insurance Co NY bought a new position in shares of Icosavax during the 3rd quarter valued at approximately $118,000. SG Americas Securities LLC bought a new position in shares of Icosavax during the 3rd quarter valued at approximately $179,000. Finally, New York State Common Retirement Fund bought a new position in shares of Icosavax during the 3rd quarter valued at approximately $180,000. 30.44% of the stock is owned by institutional investors and hedge funds.
This could be the most profitable event in crypto history. And it only happens once. If you miss it, there are no second chances.
Icosavax Company Profile
Icosavax Inc is a biopharmaceutical company which focuses on life-threatening respiratory diseases. The company’s virus-like particle platform technology involved in developing vaccines against infectious diseases. Icosavax Inc is based in SEATTLE.
Featured Story: How Do You Make Money With Penny Stocks?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $1,000 in Icosavax right now?
Before you consider Icosavax, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Icosavax wasn’t on the list.
While Icosavax currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Read More: Jefferies Financial Group Comments on Icosavax Inc’s FY2021 Earnings (NASDAQ:ICVX)